Is Supernus (SUPN) Undervalued After Joining The Nasdaq Composite?

Supernus (SUPN) has just been added to the Nasdaq Composite Index after completing its merger-driven transformation from Indivior Pharmaceuticals, bringing fresh attention to a business focused on opioid use disorder treatments.

Recent trading has been choppy for Supernus, with the share price down 22.9% on a 30 day basis and 28.1% over 90 days. However, total shareholder return over five years is 127.5%, which points to long term holders still sitting on strong gains while near term momentum has cooled despite index inclusion and the leadership reshuffle.

Scan how Supernus compares with other healthcare specialists by running through our hand picked 36 healthcare AI stocks that are also in focus after high profile catalysts and index moves.

Supernus now couples a sizable opioid treatment franchise with fresh index backing and new leadership. The real tension for investors is simple: does the recent share pullback leave that business priced attractively or not?

Most Popular Narrative: 50.1% Undervalued

Against Supernus's last close at $27.62, the analyst consensus Narrative on Simply Wall St points to a fair value of about $55.33. This implies a large gap that hinges on strong earnings power and the chosen 7.24% discount rate.

The multiyear Indivior Action Agenda, including at least $150 million in annual operating expense savings and a capped 2026 operating budget of $450 million, is intended to materially lower the cost base and support the translation of revenue growth into earnings and cash flow expansion.

See why 4 investors see Supernus as 50% undervalued.

Result: Fair Value of $55.33 (UNDERVALUED)

Still, the narrative around Supernus can shift if SUBLOCADE uptake or cost savings deviate from analyst assumptions, or if SUBOXONE Film pricing behaves differently than expected.

Find out about the key risks to this Supernus narrative.

Next Steps

Feeling uncertain about Supernus or leaning one way? Review the full picture quickly and form your own stance with 4 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Supernus?

Consider going beyond a single stock. Use the tools available and identify a few high conviction candidates before the next big catalyst appears on your watchlist.

• Target steadier compounding potential by checking companies on our 30 resilient stocks with low risk scores that focus on resilience when conditions get choppy.
• Pursue value opportunities by scanning the 33 high quality undervalued stocks for businesses that combine solid fundamentals with prices that lag underlying quality.
• Spot tomorrow's potential standouts early by reviewing the 19 high quality undiscovered gems before the broader market pays attention.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com